Cargando…
Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
INTRODUCTION: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802087/ https://www.ncbi.nlm.nih.gov/pubmed/33447025 http://dx.doi.org/10.2147/COPD.S279645 |
_version_ | 1783635699716587520 |
---|---|
author | Horne, Benjamin D Ali, Rehan Midwinter, Dawn Scott-Wilson, Catherine Crim, Courtney Miller, Bruce E Rubin, David B |
author_facet | Horne, Benjamin D Ali, Rehan Midwinter, Dawn Scott-Wilson, Catherine Crim, Courtney Miller, Bruce E Rubin, David B |
author_sort | Horne, Benjamin D |
collection | PubMed |
description | INTRODUCTION: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis evaluated the Summit Lab Score for validation as a predictor of the first episode of moderate-to-severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and other outcomes, in patients with COPD and high arterial pulse wave velocity (aPWV). METHODS: Data from a multicenter, randomized, placebo-controlled, double-blind study were retrospectively analyzed to evaluate treatment effects of once-daily fluticasone furoate/vilanterol 100/25 μg in patients with COPD and an elevated CV risk (aPWV≥11m/s) over 24 weeks. The previously derived Summit Lab Score and, secondarily, the Intermountain Risk Score (IMRS) were computed for each patient, with patients then stratified into tertiles for each score. Risk of moderate-to-severe AECOPD was analyzed across tertiles using Kaplan–Meier survival curve and Cox regression analyses. RESULTS: In 430 patients with COPD, Kaplan–Meier probabilities of no moderate-to-severe AECOPD for Summit Lab Score tertiles 1, 2, and 3 were 92.3%, 95.5%, and 85.1%, respectively (P trend = 0.015), over 24 weeks. Grouped by IMRS tertiles, the respective probabilities were 92.9%, 91.2%, and 88.3%, respectively (P trend = 0.141). Length of stay in the hospital (P = 0.034) and the hospital ward (P = 0.042) were also significantly different between Summit Lab Score tertiles but not for intensive care (P = 0.191). CONCLUSION: The Summit Lab Score was associated with the 24-week risk of moderate-to-severe AECOPD in COPD patients with elevated CV risk. Secondarily, IMRS showed a trend towards differences in the risk of AECOPD, which was not statistically significant. |
format | Online Article Text |
id | pubmed-7802087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78020872021-01-13 Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness Horne, Benjamin D Ali, Rehan Midwinter, Dawn Scott-Wilson, Catherine Crim, Courtney Miller, Bruce E Rubin, David B Int J Chron Obstruct Pulmon Dis Original Research INTRODUCTION: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis evaluated the Summit Lab Score for validation as a predictor of the first episode of moderate-to-severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and other outcomes, in patients with COPD and high arterial pulse wave velocity (aPWV). METHODS: Data from a multicenter, randomized, placebo-controlled, double-blind study were retrospectively analyzed to evaluate treatment effects of once-daily fluticasone furoate/vilanterol 100/25 μg in patients with COPD and an elevated CV risk (aPWV≥11m/s) over 24 weeks. The previously derived Summit Lab Score and, secondarily, the Intermountain Risk Score (IMRS) were computed for each patient, with patients then stratified into tertiles for each score. Risk of moderate-to-severe AECOPD was analyzed across tertiles using Kaplan–Meier survival curve and Cox regression analyses. RESULTS: In 430 patients with COPD, Kaplan–Meier probabilities of no moderate-to-severe AECOPD for Summit Lab Score tertiles 1, 2, and 3 were 92.3%, 95.5%, and 85.1%, respectively (P trend = 0.015), over 24 weeks. Grouped by IMRS tertiles, the respective probabilities were 92.9%, 91.2%, and 88.3%, respectively (P trend = 0.141). Length of stay in the hospital (P = 0.034) and the hospital ward (P = 0.042) were also significantly different between Summit Lab Score tertiles but not for intensive care (P = 0.191). CONCLUSION: The Summit Lab Score was associated with the 24-week risk of moderate-to-severe AECOPD in COPD patients with elevated CV risk. Secondarily, IMRS showed a trend towards differences in the risk of AECOPD, which was not statistically significant. Dove 2021-01-07 /pmc/articles/PMC7802087/ /pubmed/33447025 http://dx.doi.org/10.2147/COPD.S279645 Text en © 2021 Horne et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Horne, Benjamin D Ali, Rehan Midwinter, Dawn Scott-Wilson, Catherine Crim, Courtney Miller, Bruce E Rubin, David B Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness |
title | Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness |
title_full | Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness |
title_fullStr | Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness |
title_full_unstemmed | Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness |
title_short | Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness |
title_sort | validation of the summit lab score in predicting exacerbations of chronic obstructive pulmonary disease among individuals with high arterial stiffness |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802087/ https://www.ncbi.nlm.nih.gov/pubmed/33447025 http://dx.doi.org/10.2147/COPD.S279645 |
work_keys_str_mv | AT hornebenjamind validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness AT alirehan validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness AT midwinterdawn validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness AT scottwilsoncatherine validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness AT crimcourtney validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness AT millerbrucee validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness AT rubindavidb validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness |